More jobs! CARB-X also has openings

Dear All:

Building on my recent note about a search for the G20 secretariat lead, we now have CARB-X getting into job creation mode by posting 8 positions across 5 different job openings:

  • Accelerator Lead: coordinates the work of the growing accelerator network for all CARB-X-funded companies.
  • Support Team Lead (three positions): takes responsibility for managing the full range of support capabilities for 10-15 biotech and pharma companies in the Powered by CARB-X portfolio.
  • Director of Finance and Compliance: coordinates multiple partners and sub-grant recipients to ensure financial operations are in line with plans, plays a critical role in budget forecasting and planning processes, and more.
  • Project Manager: plays a critical role in the planning and execution of the funding cycles and coordination of pre-award and post-award activities.
  • Cycle Lead (two positions): takes full ownership of $20-50M funding Cycles from the preparatory stages through the three step application process, leading to the selection of a dozen or more additional companies for milestone-based awards.

As you hopefully already know, CARB-X began mid-2016 to award more than $455 million for research over a five-year period. I recently wrote about their search for new accelerators and it is good to see this continued expansion of their team. As one of the largest public-private research partnerships in the world. CARB-X is building an extraordinary pipeline of AMR-focused projects. If one of these opportunities intrigues, please check out the complete job postings online.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

The road to UNGA 2024 is paved with … reports!

Dear All, We’re now well into the run-up to the HLM (High-Level Meeting) on AMR during UNGA 2024 (the UN General Assembly, September 2024, see the 15 Apr 2023 newsletter for details). In preparation, reports providing data to support policy and decision-making are continuing to appear. Today, for example, GCOA and IDSA released their report entitled “2024

Leaving the lab: The decline in AMR R&D professionals

Dear All, The AMR Industry Alliance has today released a fascinating and disturbing report. Entitled “Leaving the Lab: Tracking the Decline in AMR R&D Professionals” (press release, report itself), its key message of “Researchers Are Leaving the AMR Field – Even as the Threat Rapidly Grows” is illustrated vividly by the report’s graphics. I’m going

ADVANCE-ID seeks antibiotic for P2/3 development Asia!

Dear All, Yow! Led by David Paterson,  ADVANCE-ID (ADVANcing Clinical Evidence in Infectious Diseases) is a research group launched March 2023 as a network of more than 30 hospitals across Asia. The exciting news is that ADVANCE-ID have just announced that they are seeking a novel antimicrobial agent vs. MDR Gram-negatives that could be advanced in the clinic

Which came first: The drug or resistance to the drug?

Dear All, Although it seems entirely reasonable that the “Which came first?” chicken vs. egg riddle can be resolved in favor of the egg, a pair of papers in CID suggest that the answer to the parallel question of “drug vs. resistance to the drug” is changing in a way that is NOT in our favor!

Scroll to Top